Our results are also in accordance with previous studies in EGFR-mutant NSCLC cells, where ablating EphA2 by genetic or pharmacological means could revert resistance to EGFR-TKIs [28,31]. Here, EPHA2 is linked to non-small cell lung carcinoma.